WallStSmart
REGN

Regeneron Pharmaceuticals Inc

NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY

$707.06
+3.02% today

Updated 2026-04-29

Market cap
$79.46B
P/E ratio
18.11
P/S ratio
5.54x
EPS (TTM)
$41.49
Dividend yield
0.46%
52W range
$475 – $820
Volume
0.7M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Regeneron Pharmaceuticals Inc (REGN) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$707.06
Consensus
$821.08
+16.13%
2030 Target
$2,518.03
+256.13%
DCF
$1,395.85
+50.83% MoS
25 analysts:
9 Buy6 Hold1 Sell

Management guidance

No specific CEO revenue guidance found in provided materials. Management has not publicly announced specific revenue targets for 2026-2030 period. Guidance relies on analyst consensus and product pipeline developments.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$4,196.72
$22.4B Rev × 20x P/S
Base case (2030)
$2,518.03
$22.4B Rev × 12x P/S
Bear case (2030)
$1,678.69
$22.4B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$13.1B$14.2B$14.3B$16.1B$17.7B$19.3B$20.8B$22.4B
Revenue growth—8.3%1.0%11.9%10.3%8.8%8.1%7.7%
EPS$43.78$45.64$44.38$46.75$54.83$62.50$70.00$77.50
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$1,754.99$1,983.90$2,136.51$2,289.12$2,518.03

Catalysts & risks

Growth catalysts
+ EYLEA HD extended dosing intervals (up to 20 weeks) FDA approval driving patient convenience and competitive positioning vs Roche Vabysmo and Novartis Beovu
+ Dupixent label expansions across multiple indications (bullous pemphigoid in Japan, allergic fungal rhinosinusitis, pediatric urticaria in EU) expanding addressable market
+ Olatorepatide (obesity drug) Phase 3 positive results in Chinese patients opening large obesity market opportunity with GLP-1 competition
+ TriNetX partnership with $200M investment providing access to 300M patient records for AI/precision medicine drug discovery acceleration
+ Pipeline advancement in oncology (fianlimab) and gene therapy programs with multiple data readouts expected 2026-2027
Key risks
- Biosimilar competition eroding EYLEA revenues as current growth rate only 0.99% YoY; generic/biosimilar pressure on core franchises accelerating
- Potential US pharmaceutical tariffs up to 100% on branded drugs impacting revenue if pricing negotiations fail or tariffs implemented
- Dupixent market saturation and competitive pressure from newer biologics and oral alternatives in immunology space
- Obesity market entry with olatorepatide faces intense competition from established GLP-1 agonists (Ozempic, Wegovy) with massive market share
- Patent cliff risks on key revenue drivers; reliance on Dupixent and EYLEA for ~60% of revenues creates concentration risk

Methodology

Regeneron Pharmaceuticals Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 25 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.